Garda Capital Partners pushed its tender offer deadline for Assertio Therapeutics from February 24 to March 17, a three-week extension that coincides with Assertio's board reaffirming its willingness to consider superior proposals. The $10.50-per-share all-cash bid, announced January 16, values the New Jersey-based pain-management pharma at roughly $260 million on a fully diluted basis. The extension language is procedural, but the timing and Assertio's simultaneous public reminder that it remains in active evaluation mode points to at least one other party conducting diligence.

Assertio's board filed an amended solicitation statement on February 21 explicitly noting that it "continues to be willing to consider alternative acquisition proposals" and that the company remains in compliance with its go-shop provisions under the merger agreement with Garda. The go-shop window technically closed February 15, but the no-solicitation covenant includes standard fiduciary-out provisions if a superior proposal emerges. Garda's tender is conditioned on a minimum of 50.1% of fully diluted shares being tendered, a low threshold that suggests confidence but also flexibility for a competing bid to surface without forcing an immediate termination fee fight.

The pharma specialty asset backdrop makes this extension more than clerical. Assertio's portfolio centers on three non-opioid pain products—Indocin, Otrexup, and Cambia—with $140 million in trailing twelve-month revenue as of Q3 2024. The company turned EBITDA-positive in 2023 after years of restructuring and debt refinancing, a profile that typically attracts small PE firms and strategic pharma acquirers hunting for bolt-on cashflow. Garda, a New York-based credit-focused firm, likely saw the opportunity through its distressed lens, but the cash generation and stable formulary presence also fit the playbook for specialty pharma consolidators. If a competing bid materializes, it will likely come from a similarly sized private platform or a larger generic manufacturer looking to pad margin without integration risk.

The March 17 deadline now synchronizes with Assertio's annual meeting season and the typical window for regulatory clearance under Hart-Scott-Rodino, which Garda filed shortly after announcement. If no competing proposal emerges by early March, the tender will likely close on schedule, but the extension suggests Garda is either managing a timing mismatch with regulatory approvals or preserving optionality for a topping bid that requires board engagement. The company's stock traded at $10.42 on February 21, a 75-cent discount to the offer price, wider than the typical 20- to 40-cent spread for deals with clean regulatory paths. That spread widened slightly after the extension announcement, indicating arbitrageurs are pricing in either deal risk or the possibility of a higher bid that delays closing.

Allocators tracking specialty pharma M&A should watch for any new 13D filings by March 3, when activist or strategic holders would need to disclose positions above 5% if they are preparing to block the tender or support a competing offer. The next data point is Assertio's Q4 earnings, expected in mid-March, which will clarify whether revenue held steady or declined, a key variable for any counterbidder's valuation. If Garda closes at $10.50, it represents a 6.2x EV/EBITDA multiple based on consensus estimates, a modest premium for a cashflow-positive specialty asset.

The quiet part is that Garda extended because someone asked for time. Whether that party delivers a binding proposal or fades by early March will determine if this was a tactical delay or the beginning of a cleaner auction.